Scholarlink

<p>Gallbladder cancer with distant lymph node metastases is typically considered unresectable and carries a poor prognosis. We present a rare case of Stage IVB gallbladder cancer with bulky hilar and para-aortic lymph node metastases successfully treated with systemic chemotherapy followed by conversion surgery. The patient received prolonged gemcitabine–cisplatin therapy, during which significant regression of nodal metastases was observed. With the subsequent addition of durvalumab, a sustained nodal response was confirmed. Twenty-four months after treatment initiation, the patient underwent extended cholecystectomy with para-aortic and hilar lymphadenectomy. R0 resection was achieved, with only one metastatic lymph node identified at resection. Histologically, the primary tumor exhibited limited response (Evans grade I), whereas the nodal disease responded markedly. At the time of writing, the patient remains recurrence-free 12&#xa0;months postoperatively. This case highlights the potential role of systemic chemotherapy—including immune checkpoint inhibition—in enabling curative-intent conversion surgery in selected patients with advanced gallbladder cancer. Careful patient selection, durable disease control, and multidisciplinary assessment may be essential to achieving favorable outcomes in such challenging cases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Durable response to chemotherapy enabling conversion surgery in stage IVB gallbladder cancer: a case successfully treated with durvalumab combined with gemcitabine plus cisplatin

  • 期刊论文

  • 发表日期：

    2025年11月14日

查看全文
  • Masahiro Yamaguchi,
  • Shunsuke Sato,
  • Yoko Kato,
  • Rihwa Om,
  • Yuji Kita,
  • Yuji Ikeda,
  • Sho Sato,
  • Ayato Murata,
  • Yuji Shimada,
  • Takuya Genda

摘要

Gallbladder cancer with distant lymph node metastases is typically considered unresectable and carries a poor prognosis. We present a rare case of Stage IVB gallbladder cancer with bulky hilar and para-aortic lymph node metastases successfully treated with systemic chemotherapy followed by conversion surgery. The patient received prolonged gemcitabine–cisplatin therapy, during which significant regression of nodal metastases was observed. With the subsequent addition of durvalumab, a sustained nodal response was confirmed. Twenty-four months after treatment initiation, the patient underwent extended cholecystectomy with para-aortic and hilar lymphadenectomy. R0 resection was achieved, with only one metastatic lymph node identified at resection. Histologically, the primary tumor exhibited limited response (Evans grade I), whereas the nodal disease responded markedly. At the time of writing, the patient remains recurrence-free 12 months postoperatively. This case highlights the potential role of systemic chemotherapy—including immune checkpoint inhibition—in enabling curative-intent conversion surgery in selected patients with advanced gallbladder cancer. Careful patient selection, durable disease control, and multidisciplinary assessment may be essential to achieving favorable outcomes in such challenging cases.